Precision molecular diagnostics company DiaCarta announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for its PCR test (QuantiVirus MPXV) to detect the mpox virus from lesion swabs. Designed to sample two segments of the mpox genome that are less susceptible to mutations, the tests will be capable of a wider detection rate, offering accelerated and more accurate results—and will be made available for use on quantitative PCR machines in authorized laboratories. As a result of its compatibility with current laboratory technology, the developers of the QuantiVirus MPXV test expect that it will be easy to integrate for health-care providers and, for patients potentially exposed to mpox, may reduce their need to isolate or take multiple tests. “I am very proud of our speed, dedication, and ability to develop the QuantiVirus MPXV test, which now places us at the forefront of combating potential problems from [mpox],” emphasized Aiguo Zhang, PhD, Founder, President, and Creative Executive Officer of DiaCarta.
May 25, 2023